Dr. Simon Pimstone received his MD from the University of Cape Town. He is an Internal Medicine specialist (FRCPC, UBC, 2001) with an interest in cardiovascular disease. Prior to his specialization, he trained as a clinical research fellow with the Department of Medical Genetics at UBC and obtained his PhD through the University of Amsterdam in cardiovascular genetics in 1998.
Dr. Pimstone serves as consultant physician at the UBC Medical and Cardiology Clinic at UBC Hospital in Vancouver. He is a founder and co-PI of the Study to Avoid cardioVascular events in BC (SAVE BC), a provincial program screening families with very premature atherosclerotic cardiovascular disease. After seeing two close friends suffer major myocardial infarctions under forty years of age, he was moved to establish a screening platform in BC to ensure we do what we can to identify high risk individuals as early as possible. SAVE BC was the solution to this challenge.
Dr. Pimstone is also a founder, Director, and President and Chief Executive Officer at Xenon Pharmaceuticals Inc., one of Canada’s leading publicly traded biotechnology companies (Nasdaq: XENE). He has also held positions on a number of life sciences and biotechnology boards.
- Screening for cardiovascular disease.
- Managing patients with high cardiovascular risk.
- Genetics of cardiovascular disease.
Dr. Pimstone is a founder and co-PI of the Study to Avoid cardioVascular events in BC (SAVE BC). It is a first-of-its kind research program in BC and Canada, with medical specialists identifying, managing and providing long term follow-up to individuals in BC with early and atherosclerotic cardiovascular disease and their first degree relatives and spouses, who are known to be at increased risk.
He was a member of the Science, Technology and Innovation Council, which reports to the Federal Ministry of Industry. At that time, he co-chaired the 2013 State of Nation report, an internationally read report benchmarking science and technology performance across OECD countries.